Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
136949-58-1
Molecular formula
C20H28I3N3O9
Molecular weight
835.2 g/mol
Drug class
Non-ionic, water-soluble, tri-iodinated X-ray contrast medium
Mechanism of action
The iodine atoms attenuate X-rays, increasing radiographic contrast in blood vessels, organs and other extracellular spaces following intravascular or other labelled administration routes. The agent is distributed in the vascular and interstitial compartments and is primarily eliminated unchanged by the kidneys.
Indications / reported uses
Diagnostic contrast enhancement for radiographic examinations, including CT and angiographic or urographic studies, according to the product label and route.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Iobitridol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Iobitridol Permitted Daily Exposure (PDE) report (the Iobitridol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Iobitridol Occupational Exposure Limit (OEL) report (the Iobitridol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.